Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481). 2001

P H Wiernik, and T Leong, and M M Oken, and R S Neiman, and T M Habermann, and J M Bennett, and S Schuster, and J H Glick
OLM Comprehensive Cancer Center, New York Medical College, Bronx 10466, USA. wiernik@jimmy.harvard.edu

Thirty-three evaluable patients with Hodgkin's disease who failed radiotherapy were treated on this phase II study with bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone given every 28 days for a minimum of eight courses. Twenty-five patients (76%; 95% CI=55.6-87.1%) achieved a complete remission, the median duration of which cannot yet be determined, but the probability of remaining in continuous complete remission at 10 years is.64. The median survival from entry on this study for all evaluable patients is 10 years, and 12 patients were alive at the time of this analysis with a median follow-up for them of 15.5 years. Of the 22 patients who died, 11 died of progressive or recurrent Hodgkin's disease and 11 died of other causes including 7 second primary neoplasms and at least one myocardial infarction. Both are now well known late complications of Hodgkin's disease treatment.

UI MeSH Term Description Entries
D008130 Lomustine An alkylating agent of value against both hematologic malignancies and solid tumors. CCNU,Belustine,Cecenu,CeeNU,NSC-79037,NSC 79037,NSC79037
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D011344 Procarbazine An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. Matulane,Natulan,Procarbazine Hydrochloride,Procarbazine Monohydrobromide,Procarbazine Monohydrochloride,Hydrochloride, Procarbazine,Monohydrobromide, Procarbazine,Monohydrochloride, Procarbazine
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D002423 Cause of Death Factors which produce cessation of all vital bodily functions. They can be analyzed from an epidemiologic viewpoint. Causes of Death,Death Cause,Death Causes
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females

Related Publications

P H Wiernik, and T Leong, and M M Oken, and R S Neiman, and T M Habermann, and J M Bennett, and S Schuster, and J H Glick
December 1994, Cancer,
P H Wiernik, and T Leong, and M M Oken, and R S Neiman, and T M Habermann, and J M Bennett, and S Schuster, and J H Glick
May 1990, Cancer,
P H Wiernik, and T Leong, and M M Oken, and R S Neiman, and T M Habermann, and J M Bennett, and S Schuster, and J H Glick
January 1983, Oncology,
P H Wiernik, and T Leong, and M M Oken, and R S Neiman, and T M Habermann, and J M Bennett, and S Schuster, and J H Glick
May 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
P H Wiernik, and T Leong, and M M Oken, and R S Neiman, and T M Habermann, and J M Bennett, and S Schuster, and J H Glick
June 1981, Archives of internal medicine,
P H Wiernik, and T Leong, and M M Oken, and R S Neiman, and T M Habermann, and J M Bennett, and S Schuster, and J H Glick
January 1983, Cancer treatment reports,
P H Wiernik, and T Leong, and M M Oken, and R S Neiman, and T M Habermann, and J M Bennett, and S Schuster, and J H Glick
November 2009, Leukemia & lymphoma,
P H Wiernik, and T Leong, and M M Oken, and R S Neiman, and T M Habermann, and J M Bennett, and S Schuster, and J H Glick
August 1998, Leukemia & lymphoma,
P H Wiernik, and T Leong, and M M Oken, and R S Neiman, and T M Habermann, and J M Bennett, and S Schuster, and J H Glick
May 1983, Cancer treatment reports,
Copied contents to your clipboard!